Prescription medicine
Prazosin First approved as Minipress
Prazosin (Minipress) is a prescription medicine with an FDA approval on record since 1976. FDA's NDC Directory lists it from 33 generic labelers, and pharmacies paid $0.0842 per prazosin 1 mg capsule in the October 7, 2026 NADAC survey.
- Generic listed
- A presentation discontinued
Check it at the source: the prazosin FDA label on DailyMed (effective March 6, 2026, Prasco Laboratories); the NDA 17442 record on Drugs@FDA; every prazosin label on DailyMed.
Highlights of the record
FDA label of March 6, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usagePrazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure.
Forms and strengths
- 1 mg
- 2 mg
- 5 mg
Capsule.
On the market
- Earliest approval on file
- June 23, 1976 Minipress, Pfizer; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 21 first September 12, 1988; 13 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 34 of which 33 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.0842 per capsule Prazosin 1 mg capsule
- Shortage (FDA)
- None current 3 past records
- Recalls by its makers (FDA)
- 10 since 2022 0 Class I among all firms' recalls; latest March 27, 2026
- FAERS reports
- 7,384 through July 30, 2026
What is prazosin used for?
From the label: indications and usagePrazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. […]
Conditions named in the indications of prazosin's FDA labels, with every medicine labeled for each:
From other prazosin labelsHigh blood pressure: INDICATIONS AND USAGE Prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure.
FDA pharmacologic class: alpha-Adrenergic Blocker.
Source: FDA drug label (Prazosin Hydrochloride), NDA017442 (Pfizer), as published by Prasco Laboratories, effective March 6, 2026 (SPL set cbe89216-7dea-43d7-b12e-44ccfb69af3d), via openFDA; the full label on DailyMed
Is there a generic for prazosin (Minipress)?
The FDA approved the first generic prazosin on September 12, 1988. 21 generic applications are approved; 13 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists prazosin from 33 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1976 earliest approval on file
- 1988 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for prazosin (Minipress)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.0842 per Prazosin 1 mg capsule, down 20% from $0.105 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Prazosin 1 mg capsule (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Prazosin 1 mg capsule | Generic | $0.0842 per capsule | $2.53 | -20% |
| Prazosin 2 mg capsule | Generic | $0.0863 per capsule | $2.59 | -6% |
| Prazosin 5 mg capsule | Generic | $0.134 per capsule | $4.01 | -10% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Is prazosin in shortage?
No prazosin presentation is listed as in shortage in the FDA Drug Shortage Database (read October 8, 2026); its 3 records are all marked to be discontinued, the latest updated April 28, 2023. ASHP keeps a separate shortage list, which can differ.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Minipress, Capsule, 1 mg (NDC 0069-4310-71) | Pfizer Inc. | To Be Discontinued | April 28, 2023 |
| Minipress, Capsule, 2 mg (NDC 0069-4370-71) | Pfizer Inc. | To Be Discontinued | April 28, 2023 |
| Minipress, Capsule, 5 mg (NDC 0069-4380-71) | Pfizer Inc. | To Be Discontinued | April 28, 2023 |
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
Has prazosin been recalled?
The FDA's Enforcement Report lists 10 recalls naming prazosin since 2022: 0 Class I (the most serious), 10 Class II, 0 Class III; 9 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| March 27, 2026 | Class II | Appco Pharma LLC | cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits. |
| October 16, 2025 | Class II | Amerisource Health Services LLC | Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable … |
| October 7, 2025 | Class II | Teva Pharmaceuticals USA, Inc | CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit … |
| April 13, 2022 | Class II | Mckesson Medical-Surgical Inc. Corporate Office | cGMP deviations: Temperature abuse |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the prazosin label say about other medicines?
The prazosin label names 12 other medicines in its interaction, contraindication or warning sections. The labels of 12 other medicines name prazosin. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Allopurinol | drug interactions | … and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however), and quinidine; … |
| Aspirin | drug interactions | … (see WARNINGS however), and quinidine; and (6) analgesics, antipyretics and anti-inflammatories–propoxyphene, aspirin, indomethacin, and phenylbutazone. |
| Chlordiazepoxide | drug interactions | … hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however), and quinidine; … |
| Colchicine | drug interactions | … tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however), and quinidine; … |
| Diazepam | drug interactions | … chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however), and quinidine; … |
| Digoxin | drug interactions | Drug Interactions Prazosin hydrochloride capsules have been administered without any adverse drug interaction in limited clinical experience to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; … |
| Indomethacin | drug interactions | … WARNINGS however), and quinidine; and (6) analgesics, antipyretics and anti-inflammatories–propoxyphene, aspirin, indomethacin, and phenylbutazone. |
| Phenobarbital | drug interactions | … chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however), and quinidine; … |
| Probenecid | drug interactions | … tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however), and quinidine; … |
| Procainamide | drug interactions | … sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however), and quinidine; and (6) analgesics, antipyretics and anti-inflammatories–propoxyphene, aspirin, indomethacin, and phenylbutazone. |
| Propranolol | drug interactions | … and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however), and quinidine; and (6) analgesics, antipyretics and anti-inflammatories–propoxyphene, aspirin, indomethacin, and phenylbutazone. |
| Quinidine | drug interactions | … antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however), and quinidine; and (6) analgesics, antipyretics and anti-inflammatories–propoxyphene, aspirin, indomethacin, and phenylbutazone. |
Other labels that name prazosin
Source: FDA drug label (Prazosin Hydrochloride), NDA017442 (Pfizer), as published by Prasco Laboratories, effective March 6, 2026 (SPL set cbe89216-7dea-43d7-b12e-44ccfb69af3d), via openFDA; the full label on DailyMed
What do FAERS reports show for prazosin?
The FDA Adverse Event Reporting System holds 7,384 reports that list prazosin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 799 are coded as a death and 2,634 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as prazosin?
75 other medicines are given the same way (oral) and in the same FDA class as prazosin or labeled mainly for the same use (high blood pressure), the same class first. High blood pressure lists all 88 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Carvedilol | High blood pressure | 41 labelers | $0.0179 per tablet 6.25 mg tablet | No current entry |
| Doxazosin | High blood pressure | 29 labelers | $0.0752 per tablet 1 mg tablet | No current entry |
| Terazosin | High blood pressure | 21 labelers | $0.106 per capsule 2 mg capsule | No current entry |
| Phenoxybenzamine | High blood pressure | 5 labelers | n/a | A presentation being discontinued |
| Metoprolol | High blood pressure | 64 labelers | $0.085 per tablet 100 mg tablet | A presentation being discontinued |
| Diltiazem | High blood pressure | 42 labelers | $0.144 per capsule 24h ER(cd) 120 mg capsule | A presentation being discontinued |
| Lisinopril | High blood pressure | 36 labelers | $0.0254 per tablet 20 mg tablet | No current entry |
| Propranolol | High blood pressure | 38 labelers | $0.0493 per tablet 20 mg tablet | In shortage |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does prazosin compare with medicines for the same use?
9 side-by-side pages set prazosin beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to prazosin
- 75 medicines for the same use
- Other alpha blockers
- the pharmacologic class, with prices and generics
- Prazosin side effects
- the label's list beside FAERS reports
- Prazosin shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other